Clinical Trial to Assess Effect of Verapamil on Systemic Exposure of EP395 and Effect of EP395 on Systemic Exposure of Midazolam and Digoxin

Conditions: Chronic Obstructive Pulmonary Disease Exacerbation; COPD Interventions: Drug: EP395 (Part A and B); Drug: Verapamil (Part A); Drug: Midazolam (Part B); Drug: Digoxin (Part B) Sponsors: EpiEndo Pharmaceuticals; CTC Clinical Trial Consultants AB Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials